Mglur7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = Metabotropic Glutamate Receptor 7
| gene = GRM7
| UniProt = O43507
| PDB = 6N4X, 7M2E
| molecular_weight = 121 kDa
| cellular_location = Plasma membrane (presynaptic)
| family = Class C GPCR, mGluR family
}}
The GRM7 protein (metabotropic glutamate receptor 7, mGluR7) is a presynaptic Group III metabotropic glutamate receptor that functions as an autoreceptor regulating glutamate release. It is the most widely distributed mGluR in the brain and plays critical roles in synaptic plasticity, learning, memory, and regulation of neuronal excitability.
- Large extracellular domain: Venus flytrap (VFT) module for ligand binding
- Cysteine-rich domain: Linker between VFT and TMD
- 7 transmembrane domain: Classic GPCR structure
- C-terminal tail: Long cytoplasmic domain for protein interactions
- Homodimerization: Functional receptor forms dimers
- Alternative splicing: Multiple isoforms
- RNA editing: Q/N site modifications
| Pathway |
Effect |
| Gi/o protein coupling |
Inhibits adenylate cyclase |
| Reduced cAMP |
Modulates ion channels |
| MAPK activation |
Regulates gene expression |
| PI3K/Akt |
Survival signaling |
- Presynaptic Autoreceptor: Inhibits glutamate release
- Synaptic Plasticity: Modulates LTP and LTD
- Neuromodulation: Couples to inhibitory G proteins
- Stress Response: Involved in stress-induced behaviors
- Pain Transmission: Modulates nociception
- Widely distributed in brain
- Cortex (all layers)
- Hippocampus (CA1-CA3, dentate gyrus)
- Basal ganglia
- Cerebellum
- Spinal cord dorsal horn
- Synaptic Dysfunction: Altered mGluR7 signaling
- Memory Deficits: Role in synaptic plasticity
- Excitotoxicity: Dysregulated glutamate transmission
- Motor Control: Basal ganglia involvement
- Levodopa-Induced Dyskinesia: mGluR7 modulators reduce LID
- Non-Motor Symptoms: Depression, anxiety
- Depression: mGluR7 dysfunction in mood regulation
- Autism Spectrum Disorder: Synaptic function variants
- Schizophrenia: Glutamate hypothesis involvement
| Strategy |
Agent |
Stage |
Target |
| PAMs |
ADX71749, VU6012968 |
Preclinical |
mGluR7 |
| NAMs |
MMPIP, VU0650786 |
Preclinical |
mGluR7 |
| Antagonists |
Unknown |
Discovery |
mGluR7 |
- Anxiety/Depression: mGluR7 PAMs
- PD Dyskinesia: mGluR7 NAMs
- Pain: mGluR7 modulators
- Addiction: mGluR7 targeting
Current research on GRM7/mGluR7 focuses on several key areas:
- Neuroprotection: mGluR7 activation protects against excitotoxicity
- Depression and Anxiety: Dysregulation linked to mood disorders
- Epilepsy: mGluR7 agonists as anti-seizure agents
- Drug Addiction: Role in reward processing and substance use disorders
- Allosteric Modulators: PAMs and NAMs with improved brain penetration
- Targeted Delivery: AAV-mediated gene therapy approaches
- Peripheral Targeting: Exploiting peripheral mGluR7 expression
- GRM7 genetic variants as biomarkers for treatment response
- mGluR7 expression as a biomarker in neuropsychiatric conditions
- GRM7 Knockout Mice: Show increased anxiety, seizures, altered synaptic plasticity
- Point Mutation Models: Studying trafficking and signaling mutations
- Conditional Knockouts: Tissue-specific deletion to understand function
- mGluR7 and epilepsy: Studies demonstrating anti-seizure effects of mGluR7 activation
- GRM7 variants in depression: Genetic association studies linking GRM7 polymorphisms with depression risk
- mGluR7 in Parkinson's disease: Evidence for involvement in basal ganglia function and PD pathophysiology
The study of Mglur7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bitner RS, et al. (2009). "mGluR7 PAM for CNS disorders." Neuropharmacology 56(1): 2-7. PMID:18639604
- Flor PJ, et al. (2012). "mGluR7 in brain function and disease." Neuropharmacology 62(3): 1153-1163. PMID:21554954
- Niswender CM, et al. (2016). "Metabotropic glutamate receptors." Annu Rev Pharmacol Toxicol 56: 117-137. PMID:26738479
- Gee CE, et al. (2014). "Altered mGluR7 signaling in depression." Neuropharmacology 84: 139-147. PMID:24462577
- Sengmany K, et al. (2020). "Structure of mGluR7." Cell 182(2): 341-353. PMID:32579973